Dynacure’s Antisense Approach To Rare Myopathies Gets Funding Boost
Ionis Collaborating On Development
France’s fledgling biotech Dynacure has pulled together a series C funding round to support its ongoing Phase I/II study of an antisense molecule for an ultrarare myopathy.
You may also be interested in...
Janssen and French biotech Dynacure take licenses to antisense candidates arising from Ionis’ Generation 2.5 technology. Merck and Cue sign autoimmune partnership, while Bayer and PeptiDream ink discovery pact.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.